Business Description
Iovance Biotherapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US4622601007
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.05 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.2 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 6.57 | |||||
Beneish M-Score | 133.31 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.2 | |||||
3-Year EPS without NRI Growth Rate | -0.2 | |||||
3-Year FCF Growth Rate | 3.6 | |||||
3-Year Book Growth Rate | -20.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 61.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 630.81 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 89.29 | |||||
9-Day RSI | 80.72 | |||||
14-Day RSI | 74.15 | |||||
6-1 Month Momentum % | -45.92 | |||||
12-1 Month Momentum % | 32.23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.15 | |||||
Quick Ratio | 4.85 | |||||
Cash Ratio | 4.41 | |||||
Days Inventory | 115.29 | |||||
Days Sales Outstanding | 89.16 | |||||
Days Payable | 199.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.4 | |||||
Shareholder Yield % | -15.62 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -44.43 | |||||
Operating Margin % | -1401.36 | |||||
Net Margin % | -1343.27 | |||||
FCF Margin % | -1222.02 | |||||
ROE % | -66.99 | |||||
ROA % | -52.11 | |||||
ROIC % | -92.77 | |||||
ROC (Joel Greenblatt) % | -255.28 | |||||
ROCE % | -61.11 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 100.17 | |||||
PB Ratio | 4.5 | |||||
Price-to-Tangible-Book | 7.47 | |||||
EV-to-EBIT | -7.13 | |||||
EV-to-Forward-EBIT | -7.69 | |||||
EV-to-EBITDA | -7.81 | |||||
EV-to-Forward-EBITDA | -7.69 | |||||
EV-to-Revenue | 99.84 | |||||
EV-to-Forward-Revenue | 19.97 | |||||
EV-to-FCF | -7.98 | |||||
Price-to-Net-Current-Asset-Value | 12.32 | |||||
Price-to-Net-Cash | 16.15 | |||||
Earnings Yield (Greenblatt) % | -14.04 | |||||
FCF Yield % | -11.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Iovance Biotherapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 32.772 | ||
EPS (TTM) ($) | -1.67 | ||
Beta | -1.27 | ||
Volatility % | 139.86 | ||
14-Day RSI | 74.15 | ||
14-Day ATR ($) | 0.658074 | ||
20-Day SMA ($) | 9.57181 | ||
12-1 Month Momentum % | 32.23 | ||
52-Week Range ($) | 3.2194 - 18.31 | ||
Shares Outstanding (Mil) | 303.51 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Iovance Biotherapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Iovance Biotherapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Iovance Biotherapeutics Inc Frequently Asked Questions
What is Iovance Biotherapeutics Inc(LTS:0JDK)'s stock price today?
When is next earnings date of Iovance Biotherapeutics Inc(LTS:0JDK)?
Does Iovance Biotherapeutics Inc(LTS:0JDK) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |